Related Experiment Videos
The impact of antianginal drug therapy on asymptomatic myocardial ischemia
1Division of Cardiology, University of South Florida College of Medicine, Tampa 33612.
Insights
Antianginal agents significantly reduce asymptomatic myocardial ischemia in stable angina patients. Both monotherapy and dual therapy proved effective, with dual therapy showing a fourfold reduction versus placebo.
Area of Science:
- Cardiology
- Pharmacology
- Internal Medicine
Background:
- Chronic stable angina pectoris frequently involves asymptomatic myocardial ischemia.
- Antianginal agents are crucial for managing angina symptoms and related ischemia.
Purpose of the Study:
- To evaluate the impact of three major antianginal agent classes on asymptomatic myocardial ischemia.
- To compare monotherapy and dual therapy efficacy in reducing ischemic events.
Main Methods:
- Patients with chronic stable angina pectoris and asymptomatic ischemia were studied.
- The effects of three classes of antianginal agents, as monotherapy and dual therapy, were assessed.
- Ischemia was quantified by episode count and ST product; age stratification was performed.
Main Results:
- Monotherapy with each agent class reduced asymptomatic ischemia by 50%.
- Dual therapy achieved a fourfold reduction in ischemia compared to placebo.
- All age groups showed similar reductions, though the youngest responded better to monotherapy.
Conclusions:
- Antianginal agents effectively reduce asymptomatic myocardial ischemia in chronic stable angina.
- Dual therapy offers superior reduction in ischemic burden compared to monotherapy.
- Age does not significantly alter the overall effectiveness of these therapies.
Abstract:
This study addresses the effect of the three major classes of antianginal agents on asymptomatic myocardial ischemia in patients with chronic stable angina pectoris. The authors found that each class (given as monotherapy) resulted in a 50% reduction in asymptomatic ischemia (both in the number of episodes and the ST product). Dual therapy resulted in an overall four fold reduction compared to placebo. Therapy also resulted in a beneficial alteration in the frequency distribution of asymptomatic ischemia. Stratification into three age groups demonstrated an equal prevalence of asymptomatic ischemia in each. All ages had nearly equivalent reductions in asymptomatic ischemia by monotherapy and dual therapy, but the youngest age group seemingly responded better to monotherapy than did the oldest age group.